Current issue #18, 2016

Panda’s bite

Court proceedings on sexual potency supplements expected soon

The issue of inspecting the sexual potency supplement market is nothing new but is still hot. By May 2016, a new feature of the case between manufacturers of such supplements and the Union of Dietary Supplement Manufacturers developed; namely, one of the manufacturers, RIA Panda, prepared a lawsuit against the Union. In turn, Union of Dietary Supplement Manufacturers Executive Director Leonid Maryanovsky is sure that there is nothing to beware. The Union’s activities aim exclusively at removing defective quality products from the market and are completely within the legal framework.

[PharmVestnik # 18, 31/05/2016, p. 1, cont’d p. 5]

Sources and amount of funding for orphan drug coverage not determined yet

As the year before, Genetika (Genetics) Association forecasts a collapse if the issue of allocating additional finance for the drug coverage of orphan disease patients is not resolved shortly. In 2015, a catastrophe was prevented due to transferring 12 bn RUB to Russia’s regions, which some experts evaluated as a one-time gusher before a large-scale All-Russia People’s Front forum. This year, in line with Genetika’s forecast, the situation has become very serious again. At the moment, it is only known that the issue of co-funding the regions is in the talking stage.

[PharmVestnik # 18, 31/05/2016, p. 2]

Plus innovations, minus oil

The 22^nd Russian Pharmaceutical Forum was held in St. Petersburg

In mid-May, the 22^nd Russian (Adam Smith) Pharmaceutical Forum was the arena for discussion of ways to overcome the recession, transfer of the Russian pharma industry to the GMP standards, drug insurance as well as current corporate affairs, which was quite traditional. Among the new topics were special investment agreements, product marking, and inspecting foreign manufacturer sites for GMP compliance by the Russian GMP Inspectorate.

[PharmVestnik # 18, 31/05/2016, p. 3]

Great Britain ready to further cooperation with Russian Pharma

A transformation of the import substitution idea becomes increasingly apparent. The slogan of “doing one’s own for oneself” has become outdated. Pharma businesses start discussing export potential development opportunities more actively. This topic was the focus of the conference “P...